+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Fina Biotech SL - Product Pipeline Analysis, 2021 Update

  • PDF Icon

    Company Profile

  • 29 Pages
  • December 2021
  • GlobalData
  • ID: 5519747
Fina Biotech SL (Fina), formerly Indas Biotech is a biotechnology projects developer that discovers new diagnostic and therapeutic techniques for the healthcare sector. The company finances, selects, develops, and markets biotechnology projects. It offers halosperm that is a kit to determine the degree of DNA fragmentation in human sperm. Fina also provides services to new tools for monitoring, diagnosis, prognosis and treatment of significant diseases and improve human health through the novelty carried out by Spanish researchers companies and research and development centers. The company’s research areas include molecular diagnostics and stem cell therapies. It provides investments in the areas of oncology, cardiology and stem cell therapy. The company collaborates with public and private institutions, medical universities, and diagnostic laboratories. Fina is headquartered in Madrid, Spain.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:


  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Fina Biotech SL
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:


  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

  • Fina Biotech SL Company Overview
  • Fina Biotech SL Company Snapshot
  • Fina Biotech SL Pipeline Products and Ongoing Clinical Trials Overview
  • Fina Biotech SL - Pipeline Analysis Overview
  • Fina Biotech SL - Key Facts
  • Fina Biotech SL - Major Products and Services
  • Fina Biotech SL Pipeline Products by Development Stage
  • Fina Biotech SL Ongoing Clinical Trials by Trial Status
  • Fina Biotech SL Pipeline Products Overview
  • Dx Bioenergetic Signature - Breast Cancer
  • Dx Bioenergetic Signature - Breast Cancer Product Overview
  • Dx Bioenergetic Signature - Colon Cancer
  • Dx Bioenergetic Signature - Colon Cancer Product Overview
  • Dx Bioenergetic Signature - Lung Cancer
  • Dx Bioenergetic Signature - Lung Cancer Product Overview
  • Dx Colon Cancer
  • Dx Colon Cancer Product Overview
  • Dx Prostate Cancer
  • Dx Prostate Cancer Product Overview
  • Dx Restenosis
  • Dx Restenosis Product Overview
  • Urobest Assay
  • Urobest Assay Product Overview
  • Urobest Assay Clinical Trial
  • Fina Biotech SL - Key Competitors
  • Fina Biotech SL - Key Employees
  • Fina Biotech SL - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Recent Developments
  • Fina Biotech SL, Recent Developments
May 25, 2018: Fina Biotech reinforces its IP portfolio with a new patent in the USA
Jan 26, 2017: Fina Biotech Receives two new patents in 2015 in the United States and in Canada, both belonging to the patent family “BLADDER CANCER DIAGNOSIS AND/OR PROGNOSIS METHOD”
May 18, 2016: Fina Biotech: Dr. Maria J. Ribal participates in the AUA 2016
Jan 26, 2016: Fina Biotech Receives Patents both in US and Canada
Appendix
  • Methodology
  • About The Publisher
  • Contact The Publisher
  • Disclaimer

List of Tables
  • Fina Biotech SL Pipeline Products and Ongoing Clinical Trials Overview
  • Fina Biotech SL Pipeline Products by Equipment Type
  • Fina Biotech SL Pipeline Products by Indication
  • Fina Biotech SL Ongoing Clinical Trials by Trial Status
  • Fina Biotech SL, Key Facts
  • Fina Biotech SL, Major Products and Services
  • Fina Biotech SL Number of Pipeline Products by Development Stage
  • Fina Biotech SL Pipeline Products Summary by Development Stage
  • Fina Biotech SL Ongoing Clinical Trials by Trial Status
  • Fina Biotech SL Ongoing Clinical Trials Summary
  • Dx Bioenergetic Signature - Breast Cancer - Product Status
  • Dx Bioenergetic Signature - Breast Cancer - Product Description
  • Dx Bioenergetic Signature - Colon Cancer - Product Status
  • Dx Bioenergetic Signature - Colon Cancer - Product Description
  • Dx Bioenergetic Signature - Lung Cancer - Product Status
  • Dx Bioenergetic Signature - Lung Cancer - Product Description
  • Dx Colon Cancer - Product Status
  • Dx Colon Cancer - Product Description
  • Dx Prostate Cancer - Product Status
  • Dx Prostate Cancer - Product Description
  • Dx Restenosis - Product Status
  • Dx Restenosis - Product Description
  • Urobest Assay - Product Status
  • Urobest Assay - Product Description
  • Urobest Assay - To evaluate the effectiveness of genetic markers in detection of bladder cancer.
  • Fina Biotech SL, Key Employees
  • Fina Biotech SL, Subsidiaries
  • Glossary

List of Figures
  • Fina Biotech SL Pipeline Products by Equipment Type
  • Fina Biotech SL Pipeline Products by Development Stage
  • Fina Biotech SL Ongoing Clinical Trials by Trial Status

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Histocell SL
  • Laboratorios Salvat SA
  • Applied Research using OMIC Sciences SL